Linan Zhu

No. 1 Jianshe East Road
Zhengzhou, 450052, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

A first-line regimen combining Bruton's tyrosine kinase and programmed cell death protein-1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma.

A first-line regimen combining Bruton's tyrosine kinase and programmed cell death protein-1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma.

Journal: Cancer

Published: September 19, 2025

Fotemustine-containing chemotherapy suggests lower toxicity with comparable efficacy versus high-dose methotrexate-based regimens: a retrospective cohort analysis.

Fotemustine-containing chemotherapy suggests lower toxicity with comparable efficacy versus high-dose methotrexate-based regimens: a retrospective cohort analysis.

Journal: Therapeutic advances in medical oncology

Published: September 04, 2025

Retraction Note: TIPE2 suppresses progression and tumorigenesis of esophageal carcinoma via inhibition of the Wnt/β-catenin pathway.

Retraction Note: TIPE2 suppresses progression and tumorigenesis of esophageal carcinoma via inhibition of the Wnt/β-catenin pathway.

Journal: Journal of translational medicine

Published: October 29, 2024

The relationship and clinical significance of serum cytokine expression level and skin pruritus in patients with Hodgkin lymphoma and angioimmunoblastic T-cell lymphoma.

The relationship and clinical significance of serum cytokine expression level and skin pruritus in patients with Hodgkin lymphoma and angioimmunoblastic T-cell lymphoma.

Journal: International immunopharmacology

Published: October 20, 2023

Clinical and therapeutical significances of the cluster and signature based on oxidative stress for osteosarcoma.

Clinical and therapeutical significances of the cluster and signature based on oxidative stress for osteosarcoma.

Journal: Aging

Published: August 01, 2023

The experience of diagnosis and treatment for TAFRO syndrome.

The experience of diagnosis and treatment for TAFRO syndrome.

Journal: Annals of hematology

Published: April 12, 2023

Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma.

Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma.

Journal: Leukemia & lymphoma

Published: January 19, 2023

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma.

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma.

Journal: Cancer medicine

Published: September 09, 2022

Real-world evidence of ABVD-like regimens compared with ABVD in classical Hodgkin lymphoma: a 10-year study from China.

Real-world evidence of ABVD-like regimens compared with ABVD in classical Hodgkin lymphoma: a 10-year study from China.

Journal: Journal of cancer research and clinical oncology

Published: July 21, 2022

The prognostic nutritional index, an independent predictor of overall survival for newly diagnosed follicular lymphoma in China.

The prognostic nutritional index, an independent predictor of overall survival for newly diagnosed follicular lymphoma in China.

Journal: Frontiers in nutrition

Published: June 29, 2022

Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial.

Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial.

Journal: JAMA oncology

Published: June 16, 2022

Clinical and Molecular Characteristics of 60 Patients With Human Immunodeficiency Virus-Negative Castleman Disease.

Clinical and Molecular Characteristics of 60 Patients With Human Immunodeficiency Virus-Negative Castleman Disease.

Journal: Frontiers in immunology

Published: March 18, 2022

Showing 1-12 of 18

Last Updated: 09/26/2026